


PHARMACEUTICAL 2022

Transcode Therapeutics Inc. Rank 180 of 475







Transcode Therapeutics Inc. Rank 180 of 475

The relative strengths and weaknesses of Transcode Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Transcode Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 217% points. The greatest weakness of Transcode Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is -42%, being 235% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	22,732
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,534
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-692
Property and Equipment	206
Research and Development	2,754
Revenues	0
Selling, General and Administrative Expense	3,397

Output Variable	Value in 1000 USD
Assets	22,938
Liabilities	2,534
Expenses	6,151
Stockholders Equity	20,404
Net Income	-6,843
Comprehensive Net Income	-6,843
Economic Capital Ratio	-42%

